Titre:
  • 18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients
Auteur:de Cremoux, Patricia; Resche-Rigon, Matthieu; Sotiriou, Christos; Groheux, David DG; Biard, Lucie; Poirot, Brigitte; Bertheau, Philippe; Teixeira, Luis; Lehmann-Che, Jacqueline; Bouhidel, Fatiha Amira; Merlet, Pascal; Espié, Marc
Informations sur la publication:Oncotarget, 9, 23, page (16343-16353)
Statut de publication:Publié, 2018-03-27
Sujet CREF:Psychiatrie
Mots-clés:18FDG-PET/CT
Breast cancer
Neoadjuvant chemotherapy
Pathological complete response
TP53 status
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1949-2553
info:doi/10.18632/oncotarget.24674
info:pii/24674
info:scp/85044473303
info:pmid/29662649